Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of GFT505 in impaired glucose tolerance and abdominal obesity
2009-011003-23Phase 2Completed
- Sponsor
- Genfit
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prediabetes and Abdominal adiposity (ABCD) comparing GFT505 80 mg once daily with Placebo once daily (2 arms). Primary endpoints: Change in Oral Glucose Tolerance Test (OGTT) and Change in VO2max. Started Mar 2009; status: completed.
02
Drugs
elafibranor
03
Conditions
prediabetesAbdominal adiposity (ABCD)
Beyond the preview
Go deeper on 2009-011003-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011003-23.